Full Press Release Details
INmune Bio Inc. to Report First Quarter
2025 Financial Results and Provide Corporate Update on Thursday, May 8th
Boca Raton, Florida, May 05, 2025 (GLOBE NEWSWIRE) -- INmune
Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage inflammation and immunology company targeting microglial
activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that it will host a conference call
on Thursday, May 8th, 2025 at 4:30pm EDT to discuss results for its quarter ended March 31, 2025 and to provide a
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes before
the beginning of the call. Please ask for the INmune Bio First Quarter Conference Call when reaching the operator.
Time: 4:30 PM Eastern Time
Participant Dial-in: 1-800-267-6316 Participant Dial-in (international):
Conference ID: INMUNE
A live audio webcast of the call can be accessed by clicking here or
A transcript will follow approximately 24 hours from the scheduled
call. A replay will also be available through May 22nd, 2025 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering
About INmune Bio Inc.
a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune
system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform
utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic
driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer's disease,
Mild Cognitive Impairment and treatment-resistant depression (XPro ). The Natural Killer Cell Priming Platform includes INKmune
developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer and is currently in trials
in metastatic castration-resistance prostate cancer. The third program, CORDStrom , is a proprietary pooled, allogeneic, human umbilical
cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic
epidermolysis bullosa. INmune Bio's product platforms utilize a precision medicine approach for diseases driven by chronic inflammation
and cancer. To learn more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that
any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained
in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject
to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these risks and uncertainties. INB03 , XPro1595, and INKmune are
still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA)
or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific
results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the Company's ability to produce more drug for clinical trials; the availability
of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies
and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing
and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings
with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K, the Company's Quarterly Reports
on Form 10-Q and the Company's Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements
in order to reflect any event or circumstance that may arise after the date of this release.
Daniel Carlson, Head of Investor Relations